Biotechnology

ARK Invest Adjusts Portfolio by Selling Palantir Shares for Crypto and Biotech Investments

ARK Invest sold over 38,000 Palantir shares, reallocating funds to crypto and biotech, reflecting a strategy to balance its investment portfolio.

Latest IPOs and Secondary Offerings You Should Know

Several companies are entering the IPO and secondary offering market, reflecting investor interest and growth funding opportunities.

YZi Labs Launches $1 Billion Builder Fund to Ignite Innovation in the BNB Ecosystem

YZi Labs has launched a $1 billion Builder Fund to support innovation in the BNB ecosystem focusing on Web3, AI, and biotech projects.

Telomir Pharma Stock Soars 35% on Epigenetic Therapy Breakthrough

Telomir Pharmaceuticals surged after new data showed its lead drug could reset disease drivers, sparking investor buzz in a high-risk biotech play.

Biogen Stock (BIIB): Strong Q2 Performance Fuels Growth

Biogen's Q2 2025 shows strong growth with new drugs boosting revenue and EPS, despite challenges in legacy MS treatments.

ProKidney Stock (PROK): Is the Hype Justified?

ProKidney's stock soared after promising Phase 2 trial results, highlighting the potential but also the risks in biotech investments.

Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development

Recursion Pharmaceuticals partners with MIT for Boltz-2, an AI model predicting binding affinity at unprecedented speed and accuracy.

Taysha Gene Therapies Stock (TSHA): Innovative Gene Therapy Focus

Taysha Gene Therapies (NASDAQ: TSHA) is gaining investor attention with TSHA-102, its lead Rett syndrome gene therapy. Learn why this biotech stock is a rising contender in the CNS space.

Cidara Therapeutics Stock (CDTX): A Notable Contender in Antivirals

Cidara Therapeutics aims to innovate antivirals with CD388, targeting flu prevention. Positive trial results may boost stock.

Vigil Neuroscience Stock (VIGL): Buyout Boosts Valuation

Vigil Neuroscience's stock soared after Sanofi agreed to buy it for $8.00 per share, tied to the potential success of its Alzheimer’s drug VG-3927.

Capricor Stock (CAPR) Launch Hype Builds on Potential Breakthrough Therapy

Capricor Therapeutics (CAPR) stock climbs as FDA decision nears for its Duchenne therapy, with peak sales forecast at $3.3B by 2038.

Geron Corp Stock (GERN): Demand Recovery on the Rise

Geron Corporation's stock (GERN) is gaining attention due to its promising biotech advancements, particularly with its lead drug, Rytelo.

CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials

CytomX Therapeutics stock surges 280% on promising cancer data and a $93.4 million stock offering, bolstering its financial future.

Iovance Biotherapeutics Stock (IOVA): Navigating Turbulent Times

Iovance shares plunged on weak Q1 results and production issues, then bounced 10% as investors reassessed. Legal risks and volatility remain high.

Northwest Biotherapeutics Stock (NWBO) Faces Challenges Ahead

Northwest Biotherapeutics (NWBO stock) bounces in pre-market trading after a steep drop, as investors reassess its high-stakes outlook amid mounting volatility.